The positive effects of paricalcitol on the reduction of proteinuria observed in patients with CKD may also be important for kidney transplant recipients: by reducing the proteinuria, progression of CKD in the transplanted kidney might be delayed and the risk for cardiovascular events reduced. This might contribute to the improvement of long-term kidney transplant survival, which has not changed significantly in the last two decades.